The following is a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks that hit 52-week highs on Jan. 8.)
Collegium Pharmaceutical Inc (NASDAQ: COLL) (announced upbeat guidance for fiscal year 2020)
Bio-Rad Laboratories, Inc. Class A (NYSE: BIO)
Dermira Inc (NASDAQ: DERM)
DexCom, Inc. (NASDAQ: DXCM)
Grifols SA - ADR ADR Class B (NASDAQ: GRFS)
Inspire Medical Systems Inc (NYSE: INSP)
Medtronic PLC (NYSE: MDT)
Nevro Corp (NYSE: NVRO)
PTC Therapeutics, Inc. (NASDAQ: PTCT)
Syneos Health Inc (NASDAQ: SYNH)
TG Therapeutics Inc (NASDAQ: TGTX)
Turning Point Therapeutics Inc (NASDAQ: TPTX)
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
Zoetis Inc (NYSE: ZTS)
None of the NYSE- or Nasdaq-listed biotech hit 52-week lows Wednesday.
Stocks In Focus Medtronic Buys Spinal Cord Stimulation Tech Company Stimgenics
Medtronic said it has acquired Illinois-based, privately held Stimgenics, a pioneer of novel spinal cord stimulation waveform known as Differential Target Multiplexed Spinal Cord Stimulation.
"The therapy, which is delivered via the Medtronic Intellis platform, is a new and unique programming option to treat patients with chronic pain," Medtronic said.
The company expects the acquisition to be neutral to fiscal year 2020 earnings per share and to meet its long-term financial metrics for acquisitions.
Merck's Keytruda Approved As Monotherapy For Bladder Cancer
Merck & Co., Inc. (NYSE: MRK) announced FDA approval for its Keytruda as monotherapy for treating patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Merck shares were trading 0.56% higher at $89.10 in Thursday's premarket session.
Applied Genetic Reports Positive Results For Gene Therapy Targeting Inherited Eye Disorder
Applied Genetic Technologies Corp (NASDAQ: AGTC) released positive interim six-month data for its ongoing Phase 1/2 study of its AAV-based gene therapy in X-linked retinitis pigmentosa.
Patients treated centrally with its product candidate showed durable improvement in visual function six months after dosing, the company said.
The data, along with the promising safety and efficacy data reported in September 2019, will help design the pivotal trial that Applied Genetics plans to initiate by the end of 2020.
Applied Genetic also said it would report interim six-month data from the dose escalation cohorts of both of its ongoing trials in achromatopsia later this month.
The stock was rallying by 51.44% to $6.30 at the time of publication Thursday.
Globus Medical Guides To FY20 Revenue, EPS Shortfall
Globus Medical Inc (NYSE: GMED) announced preliminary fourth-quarter and full-year results and said it expects fourth-quarter sales of $211 million and full-year sales of $784.7 million.
Analysts, on average, expect revenue of $209.93 million for the fourth quarter and $783.95 million for the full year.
For 2020, the company expects revenue of $850 million and non-GAAP EPS of $1.82, trailing the consensus estimates of $854.39 million in revenue and $1.92 in EPS.
The stock was down 6.02% at $55 in the premarket session.
DBV Reports Positive Study Results For Peanut Allergy Drug In Children
DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) announced positive results for the three-year, open-label extension study of the Phase 3 PEPITES trial that evaluated the long-term efficacy and safety of its investigational Viaskin Peanut in peanut-allergic children ages 4-11.
"The results demonstrate long-term clinical benefit as shown by an increase in eliciting dose, which may decrease the chance of reacting to an accidental peanut exposure," the company said.
The stock was trading 21% higher at $13.70 at the time of publication.
Mirati Announces $250M Secondary Offering
Mirati Therapeutics Inc (NASDAQ: MRTX) said it intends to offer $250 million in common shares in an underwritten public offering.
The stock was down 5.9% at $98.56 in the premarket session Thursday.
Nabriva's Contepo NDA Resubmission Accepted For Review
Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV) said the FDA acknowledged the receipt of its NDA resubmission for Contepo injection for the treatment of complicated urinary tract infections, or cUTIs. The PDUFA date has been set for June 19, 2020.
The FDA handed down a complete response letter for the Contepo NDA in cUTIs on April 30, 2019, after which the company had a Type A meeting with the regulatory agency. The FDA then classified the resubmission as Class 2, giving a six-month review period from the date of resubmission.
Nabriva shares were trading 6.5% higher at $1.31 in Thursday's premarket session.
AEterna Zentaris Violates Minimum Bid Price Listing Standard
AEterna Zentaris Inc. (NASDAQ: AEZS) said it has received a notification from the Nasdaq that the company no longer meets the minimum bid price requirement, as its shares were trading below $1 for 30 consecutive business days.
The stock was trading down 5.41% at $1.05 in the premarket session.
Related Link: 8 Biotech Stocks Morgan Stanley Recommends For 2020
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.